CARISMA THERAPEUTICS INC

Day range

$0.00 – $0.00

Open

$0.00

Prev close

$0.00

Volume

3.62K

Market cap

—

Shares out

—

P/E

0.00

P/S

0.00

P/B

0.00

P/FCF

—

ROE

-927.6%

ROA

122.7%

Debt/Equity

0.00

Div yield

—

As of Oct 23, 2026

• Delisting determinationOct 9, 2025

  On October 9, 2025, Carisma Therapeutics Inc. (the "Company") received a delisting determination letter (the "Determination Letter") from The Nasdaq Stock Market LLC ("Nasdaq"). The Determination Letter indicated that, as a result of the Company's previously disclosed noncompliance with the Nasdaq Listing Rules, the Company's common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.

• Partnership or collaborationSep 18, 2025

  On September 16, 2025, Carisma Therapeutics Inc. (the 'Company') and ModernaTX, Inc. ('Moderna') entered into a First Amendment to the Collaboration and License Agreement (the 'Amendment'), which amends that certain Collaboration and License Agreement, dated as of January 7, 2022, by and between the Company and Moderna.

• Listing deficiency noticeAug 29, 2025

  By a decision dated June 10, 2025 (the "Panel Decision"), the Nasdaq Hearings Panel (the "Panel") granted the Company's request for the transfer of its listing to The Nasdaq Capital Market ("NCM"), pursuant to an exception, ultimately through October 7, 2025, to evidence compliance with all applicable criteria for listing on the NCM, including the applicable bid price requirement (the "NCM Bid Price Rule") and complete a strategic transaction.

• Special meeting resultsAug 8, 2025

  On August 5, 2025, Carisma Therapeutics Inc. held a Special Meeting of Stockholders. The Company's stockholders adopted and approved an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split with voting results: 21,783,014 votes for, 3,352,989 votes against, and 92,853 votes abstaining.

• Listing deficiency noticeJul 15, 2025

  on January 6, 2025, The Nasdaq Stock Market LLC ('Nasdaq') notified Carisma Therapeutics Inc. (the 'Company') that, based upon the preceding 30-business day period, the Company no longer satisfied Nasdaq Listing Rule 5450(a)(1), which required the Company to maintain a minimum closing bid price of $1.00 per share for continued listing on The Nasdaq Global Market ('NGM')

• EVGNEVOGENE LTD.+0.44%

Days to cover

1.3

Short interest

6.46K

Avg volume

5.15K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders
  neutralGlobeNewswire Inc.· Jul 26, 2025
• SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders
  neutralBenzinga· Jul 16, 2025
• $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TURN, HLGN, CARM, and GNTY
  neutralBenzinga· Jul 14, 2025
• SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, CARM, ENZB on Behalf of Shareholders
  neutralGlobeNewswire Inc.· Jul 5, 2025
• SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMS, BASE, CARM, ENZB on Behalf of Shareholders
  neutralBenzinga· Jul 1, 2025